JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Vital Signs - CETP Inhibitors Promising Treatments in Development for Dyslipidemia

Vital Signs - CETP Inhibitors Promising Treatments in Development for Dyslipidemia

RELEASE DATE
17-Jan-2011

REGION
North America

Research Code: 9561-00-B8-00-00

SKU: HC00613-NA-MR_04086

$1,500.00

Special Price $1,125.00 save 25 %

In stock

SKU

HC00613-NA-MR_04086

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Description
Table of Contents
Request Sample

Description

This issue of Vital Signs, released on January 17, 2011, provides a strategic overview of CETP inhibitor treatments in development for dyslipidemia. Additionally, a company spotlight is provided for DARA BioSciences, a development stage biopharmaceutical company. Reimbursement and regulatory news from the FDA is also provided for the week of December 26, 2010.

Table of Contents

Vital Signs: 17 Jan 2011

This week's issue

Popular Topics

commercial uav market

solar cell market

virtual reality market

digital signage market

cyber security market

biofuels market

diabetes care devices market

functional food market

fleet management market

biocides market

This issue of Vital Signs, released on January 17, 2011, provides a strategic overview of CETP inhibitor treatments in development for dyslipidemia. Additionally, a company spotlight is provided for DARA BioSciences, a development stage biopharmaceutical company. Reimbursement and regulatory news from the FDA is also provided for the week of December 26, 2010.

More Information

More Information
No Index	Yes
Podcast	No
Industries	Healthcare
WIP Number	9561-00-B8-00-00
Is Prebook	No